Medtronic PLC $MDT Shares Purchased by Monte Financial Group LLC

Monte Financial Group LLC raised its holdings in shares of Medtronic PLC (NYSE:MDT) by 32.8% in the 3rd quarter, Holdings Channel reports. The firm owned 42,668 shares of the medical technology company’s stock after purchasing an additional 10,546 shares during the quarter. Monte Financial Group LLC’s holdings in Medtronic were worth $4,064,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of the business. Delos Wealth Advisors LLC bought a new stake in shares of Medtronic during the 2nd quarter valued at about $27,000. Corundum Trust Company INC acquired a new position in Medtronic in the third quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. acquired a new position in Medtronic in the third quarter valued at approximately $33,000. Tripletail Wealth Management LLC bought a new position in shares of Medtronic during the third quarter valued at approximately $34,000. Finally, GFG Capital LLC bought a new stake in shares of Medtronic in the 2nd quarter worth approximately $36,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Leerink Partners set a $120.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Friday. Stifel Nicolaus boosted their target price on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Finally, William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Fourteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Stock Down 0.4%

MDT stock opened at $100.98 on Monday. The firm’s 50-day moving average is $99.44 and its two-hundred day moving average is $95.32. The company has a market capitalization of $129.45 billion, a price-to-earnings ratio of 27.22, a price-to-earnings-growth ratio of 2.66 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the firm posted $1.26 earnings per share. The business’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).